Navigation Links
Kalorama Report: Sizable Number of Acquisitions and Joint Ventures in Molecular Diagnostics
Date:8/12/2014

NEW YORK, Aug. 12, 2014 /PRNewswire/ -- Molecular diagnostic companies are partnering to survive, according to a recent Kalorama Information report.  The healthcare market research publisher said that the 5.5 billion dollar molecular diagnostics market grew by combination last year, where possible partnerships were formed and in some cases outright purchases.  The report said numerous acquisitions and joint ventures occurred in 2013 and will change the market today.   

The finding was made in Kalorama's The World Market for Molecular Diagnostics Update, the firm's latest look at the molecular IVD segment that can be found at: http://www.marketresearch.com/redirect.asp?progid=86503&url=http%3A%2F%2Fwww%2Ekaloramainformation%2Ecom%2FMolecular%2DDiagnostics%2DMonth%2D7969379%2F.

"A dynamic market encourages players to bolster their offerings with acquisitions, collaborations and licensing agreements," said Shara Rosen, Kalorama analyst and author of the report.

The report said the complexity of molecular testing encourages companies to augment their capabilities via collaborations and licensing agreements. Examples include:

  • Exosome Diagnostics U.S. with Eli Lilly, cancer PGx
  • Illumina U.S. with Global Genomics cardiac markers
  • Life Technologies/Thermo Fisher U.S. with Merck Serono drug PG

Collaboration is not always possible with companies remaining independent entities and thus many companies made purchase to cover gaps in expertise.  Kalorama cited the following as examples of 17 significant 2013 purchases where IVD companies acquired molecular dx startups or small concerns.

  • bioMerieux's purchase of BioFire Diagnostics
  • Grifol's purchase of Novartis's blood bank testing
  • Illumina's continued expansion into clinical markets (Next Bio, Advanced Liquid Logic)
  • Qiagen's purchase of CLC Bio.
  • Sysmex's purchase of Inostics digital PCR from Indivumed

Kalorama goes into greater detail about these combinations in its report, The World Market for Molecular Diagnostics Update.   Market analysis in the covers world markets for in vitro diagnostics, particularly North America and Western Europe. Segment markets within molecular diagnostics are broken out, and trends and partnerships are given extensive discussion.

About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact:
Bruce Carlson
(212) 807-2622
bcarlson@kaloramainformation.com

Logo - http://photos.prnewswire.com/prnh/20140801/132634


'/>"/>
SOURCE Kalorama Information
Copyright©2014 PR Newswire.
All rights reserved

Related biology news :

1. Report: Captive lion reintroduction programs in Africa operate under conservation myth
2. Report: Bushmeat pushes Southern African species to the brink
3. Report: Cleanup of some contaminated groundwater sites unlikely for decades
4. Report: Water and Agriculture in Canada: Towards Sustainable Management of Water Resources
5. DNA Microarray 2013 Market Report: A Focus on Sales Growth
6. Report: Climate change to shift Kenyas breadbaskets
7. UN climate report: Pricing of CO2 emissions critical
8. UGA study finds theres not always safety in numbers when it comes to extinction risk
9. Fighting bacterias strength in numbers
10. New report puts real numbers behind history of oyster reefs
11. Moderate drinking decreases number of new brain cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2020)... N.J. (PRWEB) , ... August 25, 2020 , ... ... development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer ... upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. ...
(Date:8/21/2020)... LEXINGTON, Mass. (PRWEB) , ... August 18, 2020 ... ... novel approaches to cell therapy, today announced that the U.S. Food and Drug ... evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman ... Clinical Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection ... Expert Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... ... available for free its new white paper – Simulated Transport Methodologies. Regulatory ... today’s biologics licensing application (BLA). In response, Modality Solutions shares an explanation ...
(Date:8/3/2020)... ... , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions ... as MediVet Biologics since its formation in 2016, the company is relaunching itself under ... build on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... up to three different materials for use with CRM, neurostimulation, vascular, and related ... materials to meet specific design requirements, performance, and cost criteria; especially where solid ...
(Date:7/31/2020)... FRANCISCO (PRWEB) , ... July ... ... provider of cloud-based software for the life sciences industry, today announced the ... presentation platform designed specifically for Medical Science Liaisons (MSLs) and other field ...
Breaking Biology Technology: